LFNG and melanoma: To test the effect of Lfng disruption on the metastatic capabilities of melanoma cells, we used CRISPR/Cas9 to target Lfng in order to determine whether this may confer enhanced metastatic capabilities upon the weakly metastatic B16‐F0 cell line (Fig. S12B).